Expert Interview
Reviewing the potential of Astra Zeneca's PT027, an inhaler combining a short-acting beta2-agonist (SABA) and inhaled corticosteroid (ICS) as a rescue treatment for asthma.
Ticker(s): AZNInstitution: Memorial Healthcare
- Staff Physician, Allergy/Immunology and Clinical Assistant Professor, Department of Internal Medicine at Central Michigan University College of Medicine.
- Sees ~400 pediatric and adult patients a month with common atopic disease’s(asthma, allergic rhinitis, chronic urticaria, rhino-sinusitis, ad atopic dermatitis), a 4 patients with systemic mastocytosis
- Specific clinical interests include sever asthma, food allergy, hereditary angioedema, and immunodeficiency diseases.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
